한글목차

단백질 치료제 세계 시장, 2030년에는 4,877억 달러에 달할 전망

2023년에 3,272억 달러로 추정되는 단백질 치료제 세계 시장은 분석기간 2023-2030년에 CAGR 5.9%로 성장하여 2030년에는 4,877억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 단클론항체는 CAGR 6.4%를 기록하고, 분석기간 종료시에는 2,582억 달러에 달할 것으로 예측됩니다. 인슐린 분야의 성장은 향후 7년간 CAGR이 5.9%로 추정됩니다.

미국 시장은 983억 달러, 중국은 CAGR 5.4%로 성장할 것으로 예측

미국의 단백질 치료제 시장은 2023년에 983억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 841억 달러의 시장 규모에 달할 것으로 예측되며, 분석기간 2023년부터 2030년까지 CAGR은 5.4%입니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있고, 각각 2023년부터 2030년까지 5.1%와 4.9%의 성장이 예측됩니다. 유럽에서는 독일이 CAGR 약 4.3%로 성장할 것으로 예측됩니다.

2024년에 새롭게 선보이는 흥미로운 보고서 기능 소개

인플루언서 참여 통계에 대한 풀 액세스

디지털 아카이브와 "MarketGlass" 조사 플랫폼에 무료로 액세스할 수 있습니다. 당사의 독자적인 MarketGlass 플랫폼은 전 세계 전문가들의 창의성과 시장 지식을 통합적이고 협력적으로 발휘할 수 있도록 지원합니다. 당사의 최첨단 도구는 시장 진입자의 프라이버시와 신원을 보호하면서 세계적 수준의 시장 전망을 제공합니다. 보고서의 수치, 통계 및 시장 설명은 이 분야의 전문가와 영향력 있는 사람들이 공유한 완전히 선별된 인사이트를 기반으로 합니다.

실시간 데이터 시뮬레이터 도구와 맞춤형 보고서 작성 기능을 갖춘 인터랙티브 설문 조사에 참여할 수 있습니다.

기업 간 스마트한 의견 교환을 위한 피어 협업 인터랙티브 플랫폼에 대한 풀 클라이언트 액세스

1년간 무료 보고서 업데이트

주요 기업의 세계 시장 점유율을 포함한 경쟁 커버리지

여러 지역에 걸친 기업의 시장 입지 분석(호조/활발/틈새/마이너)

전문가/인플루언서 인터뷰, 팟캐스트, 언론 발표, 이벤트 기조연설 유튜브 동영상에 대한 접근성

2024년 세계 경제에 대한 기대

통화 긴축과 이에 따른 금리 상승으로 인한 지정학적, 경제적 불안정성이 2024년 격동적인 상황을 만들어 낼 것으로 보입니다. 중동의 적대 행위와 점점 더 잦아지는 기후 재해 등 여러 요인들이 회복의 길에 계속 압력을 가할 것으로 예상됩니다. 위험요인이 있는 반면, 디플레이션 조짐이 강해지고, 완고한 인플레이션에 대한 불안감이 완화되고, 공급망이 정상화되고, 에너지 비용 변동에도 불구하고 물가가 완만하게 상승하는 등 몇 가지 긍정적인 요인도 나타나고 있습니다. 인도와 미국을 비롯한 G21 국가들의 선거는 자본 흐름과 투자 전략에 영향을 미칠 수 있습니다. 인도가 글로벌 투자처로 주목받고 있는 가운데, 미국에 기반을 둔 하이테크 기업들은 역동적인 인재와 자본 생태계에 힘입어 계속 우위를 점할 것으로 보입니다. 실리콘밸리를 비롯한 하이테크 기회는 국내 경제가 둔화되긴 했지만 여전히 견고하고 규제 환경이 잘 정비되어 있어 높은 성장 잠재력을 추구하는 투자자들에게 여전히 매력적일 것으로 보입니다. 유럽은 긴축정책과 경기침체 리스크와의 싸움이 계속되고 있으며, 영국은 2024년 경기침체 리스크가 가장 높은 국가로 가장 어려운 전망을 보이고 있습니다. 중국은 정부 지출과 개인 소비 개선에 힘입어 성장세를 이어갈 것으로 예상되는 와일드카드가 될 것입니다. 불안정한 환경은 투자자와 기업 모두에게 기회와 도전을 동시에 가져다 줄 것으로 보입니다. 변동성을 성장의 촉매제로 받아들이고, 민첩한 투자 판단과 전략적 선견지명이 생존을 위한 핵심 요소로 작용할 것입니다.

조사 대상 기업 사례(총 16건)

• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Chugai Pharmaceutical Co., Ltd.
• Diasome Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• Generex Biotechnology Corporation
• GeneScience Pharmaceuticals Co., Ltd.
• Hualan Biological Engineering, Inc.
• Johnson & Johnson
• Kyowa Hakko Kirin Co., Ltd.
• Merck Serono SA
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Sandoz International GmbH
• Teva Pharmaceutical Industries Ltd.

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 성장 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Protein Therapeutics Market to Reach $487.7 Billion by 2030

The global market for Protein Therapeutics estimated at US$327.2 Billion in the year 2023, is expected to reach US$487.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$258.2 Billion by the end of the analysis period. Growth in the Insulin segment is estimated at 5.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $98.3 Billion, While China is Forecast to Grow at 5.4% CAGR

The Protein Therapeutics market in the U.S. is estimated at US$98.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$84.1 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.9% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 16 Featured) -

• Abbott Laboratories
• Amgen, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Chugai Pharmaceutical Co., Ltd.
• Diasome Pharmaceuticals, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Genentech, Inc.
• Generex Biotechnology Corporation
• GeneScience Pharmaceuticals Co., Ltd.
• Hualan Biological Engineering, Inc.
• Johnson & Johnson
• Kyowa Hakko Kirin Co., Ltd.
• Merck Serono SA
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Sandoz International GmbH
• Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Protein Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Hematological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Hematological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Hormonal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Protein Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Protein Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Fusion Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Fusion Protein by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Fusion Protein by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Interferon by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Interferon by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Immunologic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Immunologic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Immunologic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• JAPAN
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• CHINA
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• EUROPE
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Protein Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Protein Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• FRANCE
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 77: France Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: France 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• GERMANY
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Germany 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Germany 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 89: Italy Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Italy Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Italy 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Italy 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 95: UK Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: UK Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: UK 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 98: UK Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: UK Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: UK 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Protein Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 113: Rest of World Recent Past, Current & Future Analysis for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Rest of World Historic Review for Protein Therapeutics by Application - Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: Rest of World 16-Year Perspective for Protein Therapeutics by Application - Percentage Breakdown of Value Sales for Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders and Other Applications for the Years 2014, 2024 & 2030
  • TABLE 116: Rest of World Recent Past, Current & Future Analysis for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Rest of World Historic Review for Protein Therapeutics by Product - Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Rest of World 16-Year Perspective for Protein Therapeutics by Product - Percentage Breakdown of Value Sales for Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon and Other Products for the Years 2014, 2024 & 2030

IV. COMPETITION